Global Oral Biologics Market By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, And Other Indications) And Region (Us, Europe, Asia Pacific, Rest Of The World) – Global Forecast From 2020 To 2029
1st October 2019
find_in_page Our Research Methodology is based on the following main points:
- Data Collections and Interpretation
- Data Validation
- Final Projections and Conclusion
“Global Oral Biologics Market” is a published report at MarketResearch.biz. The global oral biologics market is expected to value at approximately US$ 3 Bn in 2020, and is projected to register CAGR of 8.2% over the 10-year forecast period. The global oral biologics market report has been segmented on the basis of indication, and region.
Oral biologics is relatively innovative treatment designed for the treatment of inﬂammatory immune-mediated conditions. Oral biologics are vital for biologic administration - to make administration the same as a small molecule. The simplicity in the use of oral biologics makes it more convenient and compliant treatment. Biological products are usually administered through the parental route of administration. Oral biologics are a novel category of drugs used in the treatment of arthritis, ulcerative colitis, and others. Due to technological advancement in the healthcare sector, a research team of Rani Therapeutics company has developed a robotic drug capsule that is used to deliver oral doses of insulin and Humira into the wall of the small intestine. The first successful human study of Robotic RaniPill Capsule results in the replacement of injections. The human study was conducted at a Clinical Research Organization (CRO) in Texas, under the Investigational Review Board (IRB) approval. Oral biologics are easy to use due to which the preference towards oral biologics is increasing among the patients. Furthermore, increasing healthcare expenditure is driving demand for novel category drugs which is fueling target market growth.
Continuously increasing research and development activities for the development of oral biologics is another significant factor driving the market growth. For example, Biocon Limited working on the development of insulin tregopil, oral prandial insulin for Type 2 diabetes. Also, Massachusetts Institute of Technology (MIT) researchers developed an oral insulin drug capsule called SOMA in February for type 1 diabetes patients to replace insulin injections. A company called Oramed Pharmaceuticals from Israel is also engaged in research and development activities for the development of ORMD-0901 which is an oral GLP-1 analog capsule. Chronic diseases and conditions are continuously increasing in the world due to changes in societal behavior and ever-rising aging populace. Biologics are becoming popular in the treatment of Chronic Diseases due to its high effectiveness. Ease in the use of oral biologics further helping the demand for oral biologics to treat chronic diseases and conditions. Therefore, increasing incidences of chronic diseases is driving demand for biologics, thereby fueling target market growth. Development of Oral biologics is difficult due to the complexity in its working against fundamental human digestive physiology, absorption and distribution, and stability achievement. Therefore, difficulties in the development of oral biologics might hamper market growth. Conducting research and development activities require a large amount of investments. Other costs related to research and development of oral biologics are also high. Thus, the availability of oral biologics is limited in the market. Therefore, the high associated cost for research and development of oral biologics might hinder market growth to a certain extent. Production of oral biologics is difficult for large molecule drugs oral route. Further, low bioavailability of proteins and peptides has resulted in the several unsuccessful projects of oral delivery of peptides and proteins - this is affecting the production of oral biologics which might obstruct market growth.
Global Oral Biologics Market Segment Analysis:
By Indication: Among the indication segments, the rheumatoid arthritis segment is projected to account for majority revenue share, and register a CAGR of 7.0% over the forecast period.
Global Oral Biologics Market Regional Analysis:
The market in North America currently accounts for highest revenue share among the regional markets, followed by Asia Pacific, Europe, and Middle East & Africa.
Key Developments by Companies
Eli Lilly and Company (Year-2018)
Contracts/Agreements; In January, the company and Livongo Health collaborated to study on real-world diabetes.
Contracts/Agreements; In January, Eli Lilly and Innovative Targeting Solutions signed a research agreement to utilize its proprietary HuTARG research platform for discovery of first in class antibody drug candidates.
Regulatory Approval; In February, Eli Lilly secured the U.S. FDA approval for Verzenio (abemaciclib) in combination with an aromatase inhibitor, to treat advanced breast cancer.
Contracts/Agreements; In May, the company entered into an agreement to acquire Armo BioSciences for a value of US$1.6 billion.
Global Oral Biologics Market Segmentation:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Other Indications
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Eli Lilly and Company
- Pfizer Inc.
- AbbVie Inc.
- Rani Therapeutics
- Gilead Sciences, Inc.
- Chapter 1 Global Oral Biologics Market Overview
- 1.1 Introduction
- 1.2 Global oral biologics market is segmented on the basis of indication, and region:
- 1.3 Drivers of Global Oral Biologics Market
- 1.4 Restraints of Global Oral Biologics Market
- 1.5 Opportunities for Global Oral Biologics Market
- 1.6 Trends of Global Oral Biologics Market
- 1.7 PEST Analysis
- 1.8 PORTER’s Five Forces Analysis
- 1.9 Macro-Economic Factors
- 1.10 Latest Oral Biologics Approvals News
- 1.11 Market Expansion Strategies
- 1.12 Value Chain Analysis
- 1.13 Market Investment Feasibility Analysis
- 1.14 Opportunity Orbits
- 1.15 Regional Market Share and BPS Analysis in Global Oral Biologics Market
- 1.16 Opportunity Map Analysis
- 1.16.1 Optimistic Scenario
- 1.16.2 Likely Scenario
- Chapter 1 Global Oral Biologics Market Overview
Frequently Asked Questions (FAQ)
Revenue from the rheumatoid arthritis segment in the global oral biologics market is projected to register a CAGR of 7% during the forecast period
The projected revenue share of the global oral biologics market in 2029 is US$ 6,297.5 Mn.
Revenue from the global oral biologics market is projected to register a CAGR of 9.6% during the forecast period
Revenue from the global oral biologics market is expected to reach at US$ 7,211.1 Mn over the forecast period
In 2022, the rheumatoid arthritis segment is projected to account for highest revenue of US$ 3,102.3 Mn
Don't just take our word. We are trusted by these great companies!